Skip to content

Zymeworks

US · ZYME #2828 by market cap Listed 2017
26.14 -0.72 -2.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 7.01 Expensive vs history 87th percentile
5-year average 4.01 · #431 of 514 in Biotechnology
P/E ratio 49.51 Expensive vs history 100th percentile
5-year average -6.84 · forward 33.53 · #64 of 77 in Biotechnology
P/S ratio 6.81 Cheap vs history 20th percentile
5-year average 14.09 · forward 5.08 · #145 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Zymeworks (ZYME) 1.81B 49.32 7.00 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value28.53 Economic moatNone UncertaintyHigh

Trading 9.1% below Morningstar's fair value estimate.

Fair value

Zymeworks Inc receives a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 8% discount to our quantitative fair value estimate of $28.53 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 7.9 sits in the top 50% globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. We believe this is a sign that shares could be cheap.

On a different note, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, ranks in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Zymeworks discussion 0 comments

Add a comment